July 27, 2020 / 10:48 AM / 17 days ago

Emergent signs $174 mln deal to make AstraZeneca's potential COVID-19 vaccine

July 27 (Reuters) - Emergent BioSolutions Inc said on Monday it signed a $174 million agreement with AstraZeneca to develop and manufacture the British drugmaker’s COVID-19 vaccine candidate.

AstraZeneca in June picked Emergent to help produce the 300 million doses of its potential COVID-19 vaccine pledged to the United States. (Reporting by Trisha Roy in Bengaluru; Editing by Shinjini Ganguli)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below